PCM
DNLI icon

Pathway Capital Management’s Denali Therapeutics DNLI Stock Holding History

Pathway Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-69,450
Closed -$1.49M – 13
2023
Q4 		$1.49M Buy
+69,450
New +$1.38M 1.67% 10
2021
Q4 		– Sell
-1,012,240
Closed -$51.1M – 6
2021
Q3 		$51.1M Buy
+1,012,240
New +$57.1M 24.47% 1

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Pathway Capital Management's DNLI Position: Q1 2024 in Review

Pathway Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 69,450 shares — an estimated $1.49M sold.

Pathway Capital Management first reported a position in DNLI in Q3 2021 and held it in 2 quarters. The position peaked at $51.1M in Q3 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Pathway Capital Management reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pathway Capital Management sold 69,450 Denali Therapeutics shares in Q1 2024, an estimated $1.49M.
  • Pathway Capital Management first reported a position in Denali Therapeutics in Q3 2021 and held it in 2 quarters.
  • Pathway Capital Management's Denali Therapeutics position peaked at $51.1M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Pathway Capital Management's 13F filing for Q1 2024, filed 2 May 2024.